Bladder cancer is the most common malignancy of the urinary tract and in many patients is metastatic at diagnosis.
Chemotherapy is the standard treatment for these patients but has serious side effects and in many patients is not tolerated. To avoid the side effects of systemic chemotherapy, patients with late stage bladder cancer have sought cryotherapy in our hospital. We reviewed data for the past 4years to evaluate the safety and efficiency of percutaneous cryotherapy in 23 patients. Within 3days after cryosurgery, all complications of bladder cancer (e.g. hematuria, urinary irritation, hypogastralgia, lumbago) had decreased to some degree. No new complications (e.g. bladder perforation) occurred and all complications had disappeared completely after 2weeks. The progression-free survival (PFS) of these patients was 14 ± 8months. There was no effect on PFS of tumor location or histopathology; however, differentiation status and tumor size influenced the therapeutic effect of percutaneous cryoablation. In conclusion, percutaneous cryotherapy may be a safe and efficacious therapeutic option in the treatment of metastatic bladder cancer.
Written by:
Liang Z, Fei Y, Lizhi N, Jianying Z, Zhikai Z, Jibing C, Jialiang L, Kecheng X. Are you the author?
1Fuda Cancer Hospital, Jinan University School of Medicine, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China; Fuda Institute of Lung Cancer, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China; Fuda Institute of Cryosurgery for Cancer, No. 2 Tangdexi Road, Tianhe District, Guangzhou 510665, China. ;
Reference: Cryobiology. 2014 Feb;68(1):79-83.
doi: 10.1016/j.cryobiol.2013.12.004
PubMed Abstract
PMID: 24368268
UroToday.com Bladder Cancer Section
